Structure-Based Design of Novel Thiazolone[3,2-a]pyrimidine Derivatives as Potent RNase H Inhibitors for HIV Therapy
Molecules · 2024
DOI: 10.3390/molecules29092120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Xuan-De Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China. Hauptthemen laut MEDLINE: Pyrimidines, Molecular Docking Simulation, Quantitative Structure-Activity Relationship, Anti-HIV Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, EU funding within the MUR PNRR Extended, RAS LR 7/07 project.
Abstract (Originalsprache)
Ribonuclease H (RNase H) was identified as an important target for HIV therapy. Currently, no RNase H inhibitors have reached clinical status. Herein, a series of novel thiazolone[3,2-a]pyrimidine-containing RNase H inhibitors were developed, based on the hit compound 10i, identified from screening our in-house compound library. Some of these derivatives exhibited low micromolar inhibitory activity. Among them, compound 12b was identified as the most potent inhibitor of RNase H (IC50 = 2.98 μM). The experiment of magnesium ion coordination was performed to verify that this ligand could coordinate with magnesium ions, indicating its binding ability to the catalytic site of RNase H. Docking studies revealed the main interactions of this ligand with RNase H. A quantitative structure activity relationship (QSAR) was also conducted to disclose several predictive mathematic models. A molecular dynamics simulation was also conducted to determine the stability of the complex. Taken together, thiazolone[3,2-a]pyrimidine can be regarded as a potential scaffold for the further development of RNase H inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China.
- Department of Life and Environmental Sciences, Department of Applied Science Biosyst, University of Cagliari, 09042 Cagliari, Italy.
- Rega Institute for Medical Research, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium.
ORCID-Profile: Angela Corona, Enzo Tramontano, Shuai Wang, Christophe Pannecouque, Erik De Clercq
Förderung
- National Natural Science Foundation of China
- EU funding within the MUR PNRR Extended
- RAS LR 7/07 project
Zitieren
APA
Zhu, X. D., Corona, A., Maloccu, S., Tramontano, E., Wang, S., Pannecouque, C., De Clercq, E., Meng, G., & Chen, F. E. (2024). Structure-Based Design of Novel Thiazolone[3,2-a]pyrimidine Derivatives as Potent RNase H Inhibitors for HIV Therapy. Molecules. https://doi.org/10.3390/molecules29092120
Vancouver
Zhu XD, Corona A, Maloccu S, Tramontano E, Wang S, Pannecouque C, et al. Structure-Based Design of Novel Thiazolone[3,2-a]pyrimidine Derivatives as Potent RNase H Inhibitors for HIV Therapy. Molecules. 2024. doi:10.3390/molecules29092120
BibTeX
@article{Zhu2024,
author = {Zhu, Xuan-De and Corona, Angela and Maloccu, Stefania and Tramontano, Enzo and Wang, Shuai and Pannecouque, Christophe and De Clercq, Erik and Meng, Ge and Chen, Fen-Er},
title = {Structure-Based Design of Novel Thiazolone[3,2-a]pyrimidine Derivatives as Potent RNase H Inhibitors for HIV Therapy},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29092120}
}
EUVIMED